ATE144523T1 - Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents

Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen

Info

Publication number
ATE144523T1
ATE144523T1 AT92401218T AT92401218T ATE144523T1 AT E144523 T1 ATE144523 T1 AT E144523T1 AT 92401218 T AT92401218 T AT 92401218T AT 92401218 T AT92401218 T AT 92401218T AT E144523 T1 ATE144523 T1 AT E144523T1
Authority
AT
Austria
Prior art keywords
production
glycosylated products
glycosylated
prodrugs
products
Prior art date
Application number
AT92401218T
Other languages
English (en)
Inventor
Jean-Claude Jacquesy
Jean-Pierre Gesson
Claude Monneret
Martine Mondon
Brigitte Renoux
Jean-Claude Florent
Michel Koch
Francois Tillequin
Hans Harald Sedlacek
Manfred Gerken
Cenek Kolar
Gilbert Gaudel
Klaus Bosslet
Joerg Czech
Dieter Hoffman
Gerhard Seeman
Hans-Ulrich Schorlemmer
Gerhard Dickneite
Original Assignee
Hoechst Sa Lab
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Sa Lab, Behringwerke Ag filed Critical Hoechst Sa Lab
Application granted granted Critical
Publication of ATE144523T1 publication Critical patent/ATE144523T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT92401218T 1991-04-30 1992-04-29 Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen ATE144523T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9105326A FR2676058B1 (fr) 1991-04-30 1991-04-30 Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.

Publications (1)

Publication Number Publication Date
ATE144523T1 true ATE144523T1 (de) 1996-11-15

Family

ID=9412404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92401218T ATE144523T1 (de) 1991-04-30 1992-04-29 Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen

Country Status (16)

Country Link
US (1) US5561119A (de)
EP (1) EP0511917B1 (de)
JP (1) JP3053646B2 (de)
KR (1) KR100254113B1 (de)
AT (1) ATE144523T1 (de)
AU (1) AU673138B2 (de)
CA (1) CA2109304C (de)
DE (1) DE69214712T2 (de)
DK (1) DK0511917T3 (de)
ES (1) ES2096735T3 (de)
FR (1) FR2676058B1 (de)
GR (1) GR3022344T3 (de)
HK (1) HK1008020A1 (de)
IE (1) IE921369A1 (de)
UA (1) UA56981C2 (de)
WO (1) WO1992019639A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610299B1 (en) * 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) * 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (de) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen
DK0648503T3 (da) * 1993-09-22 2000-10-02 Hoechst Ag Pro-prodrugs, deres fremstilling og anvendelse
FR2712888B1 (fr) * 1993-11-23 1996-02-09 Bioeurope Utilisation de alpha-D-alkylglucopyranosides et esters de ceux-ci pour la préparation de prodrogues capables de traverser la barrière hématoencéphalique, prodrogues obtenues et précurseurs de celles-ci.
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
ATE278700T1 (de) * 1995-06-27 2004-10-15 Pharmachemie Bv Anthracyclin prodrugs, verfahren zu deren herstellung und deren verwendung in der selektiven chemotherapie
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
DE19617851A1 (de) 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
GB2318471A (en) * 1996-10-18 1998-04-22 Stc Submarine Systems Ltd Semiconductor laser amplifiers for transient suppression in optical wavelength division multiplex networks
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19751587A1 (de) 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1219634A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Glycokonjugate von Cytostatika mit einem geeigneten spaltbaren Peptidlinker
AU2002251988A1 (en) * 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1238678A1 (de) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzymaktivierte cytostatische Prodrugverbindungen mit Integrin Liganden
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7217696B2 (en) 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
DE10256982A1 (de) * 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2006029065A1 (en) * 2004-09-08 2006-03-16 Goverment Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Beta-gluguronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
HUE057936T2 (hu) 2005-07-18 2022-06-28 Seagen Inc Béta-glükuronid-linker-hatóanyag konjugátumok
KR20080091180A (ko) * 2005-12-30 2008-10-09 파마이센시아 코퍼레이션 약물-폴리머 컨쥬게이트
WO2008153394A2 (en) * 2007-06-14 2008-12-18 Academisch Medisch Centrum Novel anti-inflammatory pro-drugs
JP5404624B2 (ja) * 2007-08-01 2014-02-05 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ[2,1−c][1,4]ベンゾジアゼピン−グリコシドプロドラッグ
WO2009055014A2 (en) * 2007-10-23 2009-04-30 Nektar Therapeutics Al, Corporation Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
EP2098533A1 (de) * 2008-03-07 2009-09-09 Pharmachemie B.V. Ester aus Glucuronid-Prodrugs von Anthracyclinen und Verfahren zu deren Herstellung und Verwendung bei der tumorselektiven Chemotherapie
ES2830350T3 (es) 2008-05-07 2021-06-03 Biomarin Pharm Inc Péptidos de dirección lisosómica y usos de los mismos
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
US9023813B2 (en) * 2011-04-13 2015-05-05 NuTek Pharma Ltd. Synthesis and use of glycoside derivatives of propofol
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3876993A1 (de) 2018-11-05 2021-09-15 Bayer Pharma Aktiengesellschaft Cytostatische konjugate mit integrinliganden
KR102258299B1 (ko) * 2019-03-21 2021-05-28 고려대학교 산학협력단 대장암 선택적 항암 치료진단제
WO2021057840A1 (en) * 2019-09-25 2021-04-01 Peking University Senolytic and antiinflammatory prodrugs and methods of use thereof
CN114341148B (zh) * 2019-09-25 2024-01-09 北京大学 抗衰老和抗炎前药及其使用方法
WO2021056270A1 (en) * 2019-09-25 2021-04-01 Peking University Senolytic prodrugs and methods of use thereof
WO2023057814A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder
WO2023057813A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035566A (en) * 1975-09-25 1977-07-12 Sidney Farber Cancer Institute, Inc. N-trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
ATE123414T1 (de) * 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
DE3924655A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Anthracyclin-derivate
JPH075572B2 (ja) * 1989-08-18 1995-01-25 積水化学工業株式会社 2―[2―(2―ヒドロキシフェニル)ビニルピラジンおよびその製造法
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten

Also Published As

Publication number Publication date
GR3022344T3 (en) 1997-04-30
ES2096735T3 (es) 1997-03-16
DE69214712T2 (de) 1997-05-07
CA2109304C (en) 2002-01-15
JP3053646B2 (ja) 2000-06-19
JPH06506687A (ja) 1994-07-28
EP0511917A1 (de) 1992-11-04
DE69214712D1 (de) 1996-11-28
HK1008020A1 (en) 1999-04-30
EP0511917B1 (de) 1996-10-23
AU673138B2 (en) 1996-10-31
FR2676058B1 (fr) 1994-02-25
CA2109304A1 (en) 1992-10-31
DK0511917T3 (da) 1997-04-01
FR2676058A1 (fr) 1992-11-06
AU1778892A (en) 1992-12-21
UA56981C2 (uk) 2003-06-16
IE921369A1 (en) 1992-11-04
US5561119A (en) 1996-10-01
WO1992019639A1 (fr) 1992-11-12
KR100254113B1 (ko) 2000-04-15

Similar Documents

Publication Publication Date Title
ATE144523T1 (de) Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen
HUT59558A (en) New 5-chloro-quinoline-8-oxy-alkane-carboxylic acid derivatives, process for producing and utilizing them as antidotum
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
FI111263B (fi) Uudet erytromysiinijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä sekä menetelmässä käytettävät välituoteamiinit
ATA195588A (de) Epipodophyllotoxinglucosid-4'-phosphat-derivate deren herstellung, sowie pharmazeutische zusammensetzungen hierzu
GR3035479T3 (en) Sulfonamido- and sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides, process for their preparation and their use as medicines.
HUT60784A (en) Process for producing n,o-sulfated heparosanes and pharmaceutical compositions comprising such compounds
KR0156686B1 (en) Pharmaceutical composition comprising aryl-substituted rhodanine derivatives
DE69107031D1 (de) Thexyl-trialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
HUT66234A (en) Process to prepare 4,13-dioxabicyclo(8.2.1)-tridecenon-derivatives and pharmaceutical compositions containing them
GR3002679T3 (en) Dihydropyridinamides, process for their preparation and their use in medicines
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
EP0527704A3 (en) Dyestuffs, process for their preparation and the use thereof
ZA898775B (en) Cyclopropyl-substituted azolylmethylcarbinols,processes for their preparation and their use as medicaments
EP0234348A3 (en) N-glycosyl amide derivatives, method for their preparation and their use as medicaments
FI933507A (fi) Bisyklopolyatsamakrosyklofosfonihappoja, niiden komplekseja ja konjugaatteja käytettäväksi varjoaineina ja menetelmä niiden valmistamiseksi
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
PT87563A (pt) Process for the preparation of vinylcephalosporins useful as medicaments
FI933506A (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaatteja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
ATE133177T1 (de) 3'-deamino-4'-deoxy-4'-amino-8-fluoranthracycli e und verfahren zu ihrer herstellung
DE69103388D1 (de) Thexyl-(C1-C4)alkyl-dialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
KR970006264A (ko) 신규한 6-치환-5, 8-디옥시-1, 4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
EP0575583A4 (de) Komplexe von bicyclopolyazamacrocyclo carbonsäuren ihre konjugate, verfahren zur herstellung und verwendung als radiopharmazeutika.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner